Background illustration for clinical trials search

Paid Clinical Trials Stamford

Discover 1,022 paid clinical trials in Stamford, Connecticut. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,022

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

for

Gastrointestinal Stromal Tumor (GIST),

Location: New York NY, New Haven CT, Philadelphia PA, Boston MA,

Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06655246

Phase1, Recruiting

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

for

Prostate Cancer

Location: New York NY, New Haven CT, Lebanon NH, Seattle WA

Sponsor: Yale University

Sex: Male

Age: 18+

Code: NCT06111781

Phase2, Recruiting

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

for

NSCLC (Advanced Non-small Cell Lung Cancer)

Location: New York NY, New Haven CT, Philadelphia PA, Boston MA,

Sponsor: BlossomHill Therapeutics

Sex: All

Age: 18+

Code: NCT06706076

Phase1, Phase2, Recruiting

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

for

Relapsed or Refractory Large B-cell Lymphoma

Location: New York NY, New Haven CT, Montreal, Morgantown WV,

Sponsor: Kite, A Gilead Company

Sex: All

Age: 18+

Code: NCT07479797

Phase3, Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

for

Metastatic Castration-resistant Prostate Cancer

Location: New York NY, Hartford CT, Newark DE, East Syracuse NY,

Sponsor: Amgen

Sex: Male

Age: 18+

Code: NCT07213674

Phase3, Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

for

Advanced Solid Tumor

Location: New York NY, New Haven CT, Hartford CT, Boston MA,

Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07070232

Phase1, Phase2, Recruiting

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

for

Renal Cell Carcinoma

Location: New York NY, New Haven CT, Fairfax VA, Cleveland OH,

Sponsor: HiberCell, Inc.

Sex: All

Age: 18+

Code: NCT06234605

Phase1, Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

for

Ovarian Cancer Recurrent

Location: New York NY, New Haven CT, Boston MA, Montreal,

Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT06843447

Phase1, Phase2, Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

for

Advanced Solid Tumor, Melanoma, Head and Neck Cancer,

Location: New York NY, New Haven CT, Baltimore MD, Buffalo NY,

Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06172478

Phase2, Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

for

Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary,

Location: New York NY, New Haven CT, Providence RI, Baltimore MD,

Sponsor: Volastra Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05902988

Phase1, Phase2, Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

for

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen,

Location: New York NY, New Haven CT, Boston MA, Baltimore MD,

Sponsor: Servier Bio-Innovation LLC

Sex: All

Age: 18+

Code: NCT06127407

Phase3, Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for

Advanced Solid Tumor, Advanced Malignant Neoplasm,

Location: New York NY, New Haven CT, Philadelphia PA, Newark DE,

Sponsor: PMV Pharmaceuticals, Inc

Sex: All

Age: 12+

Code: NCT04585750

Phase1, Phase2, Recruiting

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

for

Advanced Solid Tumor, PDAC, HNSCC

Location: New York NY, New Haven CT, Boston MA, St Louis MO,

Sponsor: Adcendo ApS

Sex: All

Age: 18+

Code: NCT06597721

Phase1, Recruiting

DALY II USA/ MB-CART2019.1 for DLBCL

for

Refractory Diffuse Large B Cell Lymphoma (DLBCL),

Location: New York NY, New Haven CT, Boston MA, Baltimore MD,

Sponsor: Miltenyi Biomedicine GmbH

Sex: All

Age: 18+

Code: NCT04792489

Phase2, Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

for

Delayed Graft Function, DGF, Kidney Transplant

Location: New York NY, New Haven CT, Livingston NJ,

Sponsor: Alexion Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT06830798

Phase3, Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

for

Non-small Cell Lung Cancer

Location: New York NY, Brooklyn NY, New Haven CT, Bethesda MD,

Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06350097

Phase3, Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

for

Advanced or Metastatic Solid Tumors

Location: New York NY, New Haven CT, Toronto, Grand Rapids MI,

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT06752681

Phase1, Recruiting

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

for

Solid Tumors, Sarcomas

Location: New York NY, New Haven CT, Fairfax VA, St Louis MO,

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Sex: All

Age: 18+

Code: NCT07374848

Phase1, Recruiting

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

for

Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC,

Location: New York NY, Lake Success NY, New Haven CT, Fairfax VA,

Sponsor: Neomorph, Inc

Sex: All

Age: 18+

Code: NCT07300241

Phase1, Recruiting

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

for

Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors,

Location: New York NY, Boston MA, Houston TX, Austin TX,

Sponsor: Avenzo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07193511

Phase1, Phase2, Recruiting

Paid Clinical Trials Stamford

Filter results

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Interested in new trials?

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

DALY II USA/ MB-CART2019.1 for DLBCL

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)